Available online on 15.4.2025 at http://ajprd.com

Asian Journal of Pharmaceutical Research and Development

Open Access to Pharmaceutical and Medical Research



Open Access

Review Article

The Role of Artificial Intelligence in Modern Drug Discovery and Development

Veeresh Kumar Rathour, Chitransh Saxena, Mukul Kumar, Hemant Brijay

Assistant Professor's, Faculty of Pharmacy, Future University, Bareilly, Pin Code-243503

A B S T R A C T

Drug research and discovery have been completely transformed by artificial intelligence (AI), which has improved the precision and efficiency of crucial procedures. Conventional medication development is frequently risky, expensive, and slow. From target discovery to clinical trial design, artificial intelligence (AI) can speed up several phases of drug development with machine learning (ML) and deep learning (DL) algorithms. Early on, the identification of new therapeutic targets is made possible by AI models' ability to forecast possible drug-target interactions. Additionally, by evaluating enormous chemical databases to determine which molecules are most likely to display the necessary biological activity, AI optimizes lead discovery by facilitating high-throughput screening of compounds.

AI is also essential for drug repurposing, which is the process of finding new therapeutic uses for already-approved medications. AI can improve safety profiles by identifying trends in patient data that can be used to forecast unfavorable drug interactions. Furthermore, more precise in silico modeling is made possible by AI-driven simulations, which eliminates the need for expensive and time-consuming laboratory testing.

AI-enabled clinical trials further improve result prediction, patient monitoring, and patient selection. AI can predict efficacy, find appropriate trial candidates, and expedite trial design by examining genomic data and electronic health information.

The article explores how artificial intelligence (AI) is revolutionizing the entire drug development process, stressing both its present uses and its potential to change the pharmaceutical sector in the future and eventually result in the quicker and more affordable creation of new treatments.

Key words: Artificial intelligence, algorithms, Revolutionizing, machine learning

A R T I C L E I N F O: Received 11 Jan 2025; Review Complete 27 Feb .2025; Accepted 16 March 2025 ; Available online15 April. 2025

Cite this article as:

Rathour VK, Saxena C, Kumar M, The Role of Artificial Intelligence in Modern Drug Discovery and Development,, Asian Journal of Pharmaceutical Research and Development. 2025; 13(2):79-81, DOI: http://dx.doi.org/10.22270/ajprd.v13i2.1544

*Address for Correspondence:
Veeresh Kumar Rathour, Assistant Professor's, Faculty of Pharmacy, Future University, Bareilly, Pin Code-243503

INTRODUCTION

Finding and developing new drugs is a difficult, costly, and time-consuming process. A new drug's development often costs billions of dollars and takes more than ten years. This field has seen a revolution in the use of AI, which provides data-driven insights and automation to expedite several phases of drug research. Artificial Intelligence (AI) uses neural networks, computational models, and algorithms to improve clinical trials, forecast efficacy, and improve medication formulation.With an emphasis on target identification, molecular docking, medication repurposing, and clinical trial optimization, this paper examines how artificial intelligence is affecting contemporary drug discovery. Also covered are the difficulties and potential applications of AI in drug development.

AI in Drug Discovery

Target Identification and Validation

Through the analysis of genomic, proteomic, and transcriptomic data, AI-driven computational biology techniques assist in the identification and validation of pharmacological targets. Precision medicine is improved by machine learning algorithms that analyze large datasets to find new biomarkers and genes linked to disease. Natural language processing (NLP) and deep learning are two AI-

based methods that are frequently utilized to glean insightful information from genomic databases and medicinal literature.

De Novo Drug Design

Variational autoencoders (VAEs) and generative adversarial networks (GANs) are two examples of AI-driven generative models that have transformed de novo drug design. These models produce new molecular structures with pharmacokinetic and pharmacodynamic characteristics that are tuned. Artificial intelligence (AI) techniques like Deep Chem, Chem Prop, and GENTRL speed up molecular optimization and eliminate the need for a lot of trial-and-error testing.

Virtual Screening and Molecular Docking

The identification of lead compounds with high binding affinities is improved by molecular docking and AI-based virtual screening methods. The selection of possible medication candidates is made possible by deep learning models that forecast molecular interactions. AI is used by programs like AlphaFold, AtomNet, and AutoDock to forecast protein-ligand binding and enhance drug-like compounds.

Drug Repurposing

By examining current drug databases to find novel therapeutic applications for licensed medications, artificial intelligence (AI) makes drug repurposing easier. To find new drug-disease correlations, machine learning (ML) algorithms analyze real-world data, such as omics datasets and electronic health records (EHRs). Benevolent AI and Insilico Medicine are two examples of companies that use AI to find different uses for drugs.

AI In Drug Development

Pharmacokinetic and pharmacodynamic modeling

Drug candidates' absorption, distribution, metabolism, excretion, and toxicity (ADMET) characteristics are predicted by AI-driven models. By improving in silico predictions, machine learning methods like support vector machines and random forests lessen the need for intensive preclinical testing.

Clinical Trial Optimization

By choosing appropriate patient populations, streamlining trial procedures, and anticipating side effects, AI simplifies the design of clinical trials. Predictive analytics is used by AI-powered platforms like as Medidata and IBM Watson to increase trial success rates. Clinical trial data is analyzed using NLP algorithms to produce insights for tailored therapy.

Regulatory Compliance and Drug Safety

AI is used by regulatory bodies, like as the FDA and EMA, to evaluate drug safety and compliance. To guarantee post-market surveillance, AI models examine real-world data and adverse event reports. Automation of regulatory submission procedures powered by AI improves efficiency and accuracy.



Challenges and Ethical Consideration

- Despite its benefits, artificial intelligence in drug discovery has a number of drawbacks.
- Bias and Data Quality: AI algorithms rely on broad, high-quality datasets; prediction errors might result from biased data.
- Transparency and Interpretability: Understanding the results of deep learning models can be difficult because they frequently operate as "black boxes."
- Regulatory and Ethical Issues: In AI-driven medication development, it can be difficult to ensure adherence to ethical standards and regulatory frameworks.
- Integration with Experimental Research: It is necessary to balance computational and laboratory research in order to validate AI predictions through experimental studies.

Future Perspective

With developments in federated learning, quantum computing, and AI-driven automation, the use of AI in drug discovery has a bright future. Drug development will be greatly improved by combining AI with precision medicine and omics technology. The creation of novel treatments will be accelerated by cooperation between AI researchers, pharmaceutical firms, and regulatory agencies.

CONCLUSION

To sum up, artificial intelligence (AI) is changing the way that drugs are discovered and developed today by providing previously unheard-of chances to improve accuracy, lower prices, and speed up procedures. AI is revolutionizing early-stage drug research with its capacity to scan large datasets, find new drug targets, and forecast chemical interactions. Artificial intelligence (AI) techniques, particularly machine learning and deep learning, make it possible to screen compounds more effectively, improving the identification of prospective medication candidates. Artificial intelligence (AI)-powered algorithms have demonstrated great promise in drug repurposing, finding novel therapeutic applications for already-approved drugs.

Another significant impact area is the incorporation of AI in clinical trials. AI facilitates patient enrollment, tracks trial progress, and improves outcome prediction by utilizing genomic data, electronic health records, and predictive models. This increases patient safety and treatment effectiveness in addition to trial efficiency.

Notwithstanding these developments, issues like data quality and regulatory concerns still need to be resolved if AI is to realize its full potential. But as AI technologies advance, they have the potential to revolutionize the drug discovery process, making it quicker, more affordable, and better able to satisfy the demands of contemporary medicine.

REFERENCES

1. In 2018, Zhavoronkov, A. Artificial Intelligence for the Development of Novel Chemistry, Biomarker Development, and Drug Discovery. Molecular Pharmaceutics, 2018;15(10): 4311–4313.
2. Clark, D., Czodrowski, P., Vanathevan, J., et al.. Machine learning applications in medication development and discovery. Nature Reviews Drug Discovery 2019; 18(6):463–477;
3. Zorn, K. M., Ekins, S., Puhl, A. C., et al. Utilizing machine learning to find and develop drugs from start to finish, Nature Materials, 2019; 18(5): 435–441.
4. Swanson, K., Yang, K., Stokes, J. M., et al. A Deep Learning Method for Finding Antibiotics. 2020; 180(4):688–702.e13; Cell.
5. Chen, H., Olivecrona, M., Engkvist, O., Wang, Y., & Blaschke, T. Deep learning's ascent in drug discovery. in Drug Discovery Today, 2018; 23(6): 1241–1250
6. Gawehn, E., Schneider, G., & Hiss, J. A. Drug discovery using deep learning. 2016; 35(1):3–14; Molecular Informatics.
7. Preuss, M., Waller, M. P., & Segler, M. H. S. (2018). Using symbolic AI and deep neural networks to plan chemical syntheses. in Nature, 2018; 555(7698): 604–610.
8. Grisoni, F., Schneider, G., & Jimenez-Luna, J. Explainable artificial intelligence in drug discovery. in Nature Machine Intelligence, 2020; 2(10): 573–584.
9. Shenoy, S., Paul, D., Sanap, G., et al. Artificial intelligence in the development of new drugs. in Drug Discovery Today, 2021; 26(1): 80–93.
10. Mak, K. K., and Pichika, M. R. Drug discovery using artificial intelligence: current state and potential future developments. Today, Drug Discovery, 2019; 24(3):773–780.
11. Chan, H. C. S., Shan, H., Vogel, H., Dahoun, T., & Yuan, S. Using artificial intelligence to advance drug discovery. 2019; 40(8):592–604; Trends in Pharmacological Sciences.
12. Mamoshina, P., Putin, E., Zivoronkov, A., & Vieira, A. Deep learning applications in biomedicine. in Molecular Pharmaceutics, 2016; 13(5): 1445–1454.
13. Atas, H., Martin, M. J., Rifaioglu, A. S., et al. Current techniques, resources, and databases for in silico drug discovery using deep learning and machine intelligence. Bioinformatics Briefings, 2019; 20(5), 1878-1912.
14. Zhang, L., Tan, J., Han, D., and Zhu, H. Advances in artificial intelligence for logical drug discovery: from machine learning to deep learning. in Drug Discovery Today, 2017; 22(11):1680–1685.
15. Goh, G. B., Vishnu, A., & Hodas, N. O. For computational chemistry, deep learning. in Journal of Computational Chemistry, 2017; 38(16):1291–1307.
16. Lacchia. Drug discovery using deep learning: potential, obstacles, and opportunities. Drug Discovery Today, (2019); 24(10):2017–2032.
17. A. Mullard. Pharmaceutical companies are interested in AI-powered medication discovery. in Nature Reviews Drug Discovery, (2021); 20(10): 725–727.
18. Murcko, M., Walters, W. P., & Murcko, M. A.. Evaluating how pharmaceutical chemistry is affected by generative AI. in Nature Biotechnology, (2020);38(2):143–145.
19. Schneider, G. Drug discovery automation. in Nature Reviews Drug Discovery, 2018; 17(2): 97–113.
20. Clark, D., Czodrowski, P., Vanathevan, J., et al. Machine learning applications in medication development and discovery. Nature Reviews Drug Discovery (2019); 18(6): 463–477.
21. Zorn, K. M., Ekins, S., Puhl, A. C., et al. Utilizing machine learning to find and develop drugs from start to finish, Nature Materials, (2019); 18(5):435–441.
22. Swanson, K., Yang, K., Stokes, J. M., et al. A Deep Learning Method for Finding Antibiotics. (2020); 180(4):688–702.e13; Cell.
23. Chen, H., Olivecrona, M., Engkvist, O., Wang, Y., & Blaschke, T. Deep learning's ascent in drug discovery. 1241–1250 in Drug Discovery Today, (2018); 23(6).
24. Schneider, G., Hiss, J. A., and Gawehn, E. Drug discovery using deep learning. (2016); 35(1):3–14; Molecular Informatics.
25. Waller, M. P., Segler, M. H. S., and Preuss, M.. Using symbolic AI and deep neural networks to plan chemical syntheses. in Nature, (2018); 604–610:555(7698).
26. Opera, T. I., and Hasselgren, C. Are We Nearing the End of Artificial Intelligence in Drug Discovery? Toxicology and Pharmacology Annual Review, 2023; 64:1–20.
27. Abbas and associates AI's function in drug discovery. E202300816 in ChemBioChem, 2024; 25(5).
28. V. D. Mouchlis et al. De Novo Drug Design Advances: Moving from Traditional to Machine Learning Approaches. Molecular Sciences International, 2021; 22(4):1676.
29. J. Vamathevan and colleagues. Machine learning applications in drug development and discovery. in Nature Reviews Drug Discovery, (2019);18(6): 463–477.
30. S. Ekins and colleagues. Using Machine Learning for Complete Drug Development and Discovery. Nature Materials, (2019);18(5):435–441.
31. Stokes and colleagues. A Deep Learning Method for Finding Antibiotics. (2020);180(4):688-702.e13; Cell.
32. Chen and colleagues. Deep learning's ascent in drug discovery. in Drug Discovery Today (2018); 23(6):1241–1250.
33. E. Gawehn and colleagues. Drug discovery using deep learning. (2016);35(1):3–14; Molecular Informatics.
34. M. H. S. Segler and associates. Using Symbolic AI and Deep Neural Networks to Plan Chemical Syntheses. in Nature, 555(7698).
35. 2018); 604-610.
36. J. Jimenez-Luna and associates. Explainable Artificial Intelligence in Drug Discovery. in Nature Machine Intelligence (2020);573-584:2(10).